Evaluation of the diabetogenic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: a pilot study

• Main Authors: Tannaz Dehpouri (Author), Ghasem Rahmatpour Rokni (Author), Nematollah Ahangar Narenjbon (Author), Mohamad Goldust (Author), Paul S. Yamauchi (Author), Uwe Wollina (Author), Torello Lotti (Author), Leon Kircik (Author), Vito Giuseppe Di Lernia (Author), Sidharth Sonthalia (Author), Alexandra Vojvodic (Author), Jacek Szepietowski (Author), Philippe Bahadoran (Author), Enzo Errichetti (Author), Carmen Cantisani (Author), Laura Atzori (Author), Elham Rezaee (Author), Zekayi Kutlubay (Author), Burhan Engin (Author), Steven Nisticò (Author), Giovanni Damiani (Author), Rosalynn R.Z. Conic (Author), Andy Goren (Author), Leo Čabrijan (Author), Georgi Tchernev (Author)
• Format: Book
• Published: PAGEPress Publications, 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Methotrexate is a systemic immunosuppressant drug that is used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis and hypertension. This study aimed at exploring the possible...